

Press release

May 25<sup>th</sup>, 2018

### Fina Biotech reinforces its IP portfolio with a new patent in the USA

Fina Biotech announces that the United States Patent and Trademark Office (USPTO) has recently granted patent number 9,902,998 to protect a '**NON-INVASIVE DIAGNOSTIC METHOD FOR DIAGNOSING BLADDER CANCER**'. The patent will be in force until January 31<sup>st</sup> 2034 .

The object of this patent relates to a non-invasive bladder cancer diagnosis method based on the detection and quantification in spontaneous urine of the gene expression of certain genes and/or combinations thereof acting as genetic markers of said disease. Likewise, the use of said genes as bladder cancer diagnosis genetic markers is an object of the present invention, developed by **Fina Biotech** in collaboration Dr. Antonio Alcaraz and his team at the Hospital Clinic de Barcelona (Spain). Another object of the patent also relates to a bladder cancer diagnosis kit based on the use of several combinations of said genes that have proven to be useful to non-invasively diagnose bladder cancer.

This new patent strengthens the intellectual property portfolio of Fina Biotech and confirms the company's strategic commitment in developing non-invasive diagnostic tools useful for patients, doctors and healthcare providers.

**Fina Biotech S.L.** ([www.finabiotech.es](http://www.finabiotech.es)) is a spin-off of Laboratorios Indas ([www.indas.com](http://www.indas.com)), with a strong pipeline of biotechnology projects and a proven track record in product development. Fina Biotech has invested close to €12 million in 28 projects in the diagnostics and cell therapy fields, most of them in partnership with public and private institutions, laboratories and universities. A product developed by Fina Biotech, a diagnostic test for male infertility (Halosperm®) is already marketed. A bladder cancer diagnostic test based on RT-qPCR technology has already been validated in clinical studies and has proven to have better sensitivity and specificity than competitive products (10-gene signature results: SN=80% and SP=94%). .

**Biofina Diagnostics S.L.** ([www.biofinadx.com](http://www.biofinadx.com)) is born to further develop and take the bladder cancer diagnostic test to the market. The company holds the exclusive exploitation and commercialization rights on Fina Biotech's patents protecting the diagnostic method.